In summary, this prospective observational study demonstrated that the frequency of PD-1+ and LAG-3+ T cells were correlated with clinical outcomes and prognosis of relapsed/refractory multiple myeloma patients, which might also be used as potential biomarkers for the relapsed/refractory stage. Here, LAG3 is linked to AL amyloidosis.